Poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for BRCA1/2-mutant pancreatic cancer, opening a new era for targeted therapy for this disease. This evidence concerns the gene PARP1 and familial pancreatic carcinoma.